This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In case you missed it, this week we had stories about medication-related disaster preparedness, COVID-19 and cardiovascular risks, legal battles over inflated insulin prices, and more.
SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according to a person familiar with the situation and employee posts on social media. It is the latest in a series of retrenchments by high-profile gene-editing companies. A spokesperson for SalioGen declined to comment.
Imagine your nonprofit’s donor database is suddenly lost, sensitive information exposed, website taken down, all because of a single click or missed update. For nonprofits, cybersecurity isn’t just about protecting data; it’s about safeguarding the trust your supporters place in you and ensuring the you can continue your mission.
Readers of The Honest Apothecary Re-Imagined are coming to learn that this blog has now become the home for short articles and thoughts on a wide variety of topics, well beyond the walls of the pharmacy. I still love medicine. But I needed a home for all the things I care deeply about. In that […] The post A Story in Five Colors – and simplify, simplify!
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Join the 75 Hard for Pharmacy Owners program to transform yourself and your pharmacy in Q4. You might think the only way to make massive changes in your pharmacy is to complete massive projects and changes. However, as an independent pharmacy owner, I’ve found that it’s not the massive changes but the small, consistent actions that can make the biggest difference.
The American Thyroid Association defines hypothyroidism as a result of an “underactive thyroid gland.” Common symptoms include fatigue, cold sensitivity, dry skin, weight gain, hair loss, high cholesterol, or constipation. The recommended treatment is replacing the body with T4 (levothyroxine). Currently, the guidelines recommend one standard treatment, but there are other options available.
Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year.Marstacimab will be launched as Hympavzi to treat haemophilia A without factor VIII inhibitors and haemophilia B without factor IX inhibitors in patients aged 12 and older and is the first drug in the anti-TFPI class to be approved in the US.
Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year.Marstacimab will be launched as Hympavzi to treat haemophilia A without factor VIII inhibitors and haemophilia B without factor IX inhibitors in patients aged 12 and older and is the first drug in the anti-TFPI class to be approved in the US.
By Mark A. Tobolowsky — The Rare Pediatric Disease Priority Review Voucher program has had a bit of a tumultuous history in its 12 short years of existence. Designed to incentivize the development of drugs for pediatric rare diseases where such development may not otherwise have occurred, vouchers may be granted for drugs for serious or life-threatening rare diseases where the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content